GCC, Levant, Maghreb, three distinct regulatory and commercial realities within MENA. Discover why sub-regional precision determines market entry success, and what treating MENA as one market actually costs. | Nexus Pharmalink

Co-promotion agreements give pharma companies access to established MENA sales infrastructure; however, only if structured correctly. Discover the five dimensions that determine co-promotion agreement value. | Nexus Pharmalink

Europe holds 30% of the global pharma market and is a primary source of in-licensing opportunities for MENA companies. Discover why EMA approval status changes the regulatory equation for MENA submissions. | Nexus Pharmalink

North America holds 42% of the global pharma market and leads global R&D. Discover how MENA companies access North American innovation, and why the Santé Canada regulatory advantage changes the equation. | Nexus Pharmalink

MENA pharma companies are actively seeking Western innovation, in-licensing, co-development, and biotech access. Discover the bidirectional partnership model that creates value for both sides. | Nexus Pharmalink

Saudi Vision 2030 permanently changed MENA pharma entry rules, technology transfer is now commercially superior to pure licensing. Learn what this means for your market entry strategy. | Nexus Pharmalink

70% of pharma expansions into MENA fail. Discover the 4 critical mistakes and the Nexus approach to securing your market entry. Expert guide by Sara Abbad.